184 related articles for article (PubMed ID: 37106265)
1. An HPK1 inhibitor enhanced the tumour response to anti-PD-1 immunotherapy in non-Hodgkin's lymphoma.
Yang L; Zhao Q; Chen T; Liu W; Qiu X; Chen J; Huang S; Huang R; Dong L
Clin Exp Med; 2023 Nov; 23(7):3767-3780. PubMed ID: 37106265
[TBL] [Abstract][Full Text] [Related]
2. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological inhibition of HPK1 synergizes with PD-L1 blockade to provoke antitumor immunity against tumors with low antigenicity.
Setsu G; Goto M; Ito K; Taira T; Miyamoto M; Watanabe T; Higuchi S
Biochem Biophys Res Commun; 2024 Jun; 715():149995. PubMed ID: 38685185
[TBL] [Abstract][Full Text] [Related]
4. Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin's lymphoma.
Lurain K; Ramaswami R; Mangusan R; Widell A; Ekwede I; George J; Ambinder R; Cheever M; Gulley JL; Goncalves PH; Wang HW; Uldrick TS; Yarchoan R
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33608378
[TBL] [Abstract][Full Text] [Related]
5. NLRP3 inflammasome upregulates PD-L1 expression and contributes to immune suppression in lymphoma.
Lu F; Zhao Y; Pang Y; Ji M; Sun Y; Wang H; Zou J; Wang Y; Li G; Sun T; Li J; Ma D; Ye J; Ji C
Cancer Lett; 2021 Jan; 497():178-189. PubMed ID: 33091534
[TBL] [Abstract][Full Text] [Related]
6. STAT3 Expression and Its Correlation with PD-L1 Expression in Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma at Dr. Saiful Anwar Regional Public Hospital in Malang, Indonesian Population.
Hambalie AO; Norahmawati E; Endharti AT; Retnani DP; Rahmadiani N
Adv Hematol; 2024; 2024():7989996. PubMed ID: 38817669
[TBL] [Abstract][Full Text] [Related]
7. Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study.
Eisenbeis CF; Grainger A; Fischer B; Baiocchi RA; Carrodeguas L; Roychowdhury S; Chen L; Banks AL; Davis T; Young D; Kelbick N; Stephens J; Byrd JC; Grever MR; Caligiuri MA; Porcu P
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6101-10. PubMed ID: 15447996
[TBL] [Abstract][Full Text] [Related]
8. Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor.
You D; Hillerman S; Locke G; Chaudhry C; Stromko C; Murtaza A; Fan Y; Koenitzer J; Chen Y; Briceno S; Bhadra R; Duperret E; Gullo-Brown J; Gao C; Zhao D; Feder J; Curtin J; Degnan AP; Kumi G; Wittman M; Johnson BM; Parrish KE; Gokulrangan G; Morrison J; Quigley M; Hunt JT; Salter-Cid L; Lees E; Sanjuan MA; Liu J
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33408094
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells.
Sakakibara A; Kohno K; Eladl AE; Klaisuwan T; Ishikawa E; Suzuki Y; Shimada S; Nakaguro M; Shimoyama Y; Takahara T; Kato S; Asano N; Nakamura S; Satou A
Histopathology; 2018 Jun; 72(7):1156-1163. PubMed ID: 29380399
[TBL] [Abstract][Full Text] [Related]
10. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
[TBL] [Abstract][Full Text] [Related]
11. Incidence and Risk Factors of Infections Among Diffuse Large B-cell Lymphoma and Classical Hodgkin's Lymphoma Patients in a Tertiary Care Center in Saudi Arabia: A Retrospective Cohort Study.
Alelyani RH; Alghamdi AH; Almughamisi TA; Alshareef AM; Kadasa AN; Alrajhi AM; Alburayk AK; Barefah AS; Radhwi OO; Almohammadi AT; Bahashawan SM; AlAhwal HM
Cureus; 2023 Mar; 15(3):e35922. PubMed ID: 36911585
[TBL] [Abstract][Full Text] [Related]
12. The P2X7 receptor-NLRP3 inflammasome complex predicts the development of non-Hodgkin's lymphoma in Sjogren's syndrome: a prospective, observational, single-centre study.
Baldini C; Santini E; Rossi C; Donati V; Solini A
J Intern Med; 2017 Aug; 282(2):175-186. PubMed ID: 28503820
[TBL] [Abstract][Full Text] [Related]
13. Highly potent, orally active novel small-molecule HPK1 inhibitor DS21150768 induces anti-tumor responses in multiple syngeneic tumor mouse models.
Setsu G; Goto M; Ito K; Taira T; Miyamoto M; Watanabe T; Taniguchi T; Umezaki Y; Nakazawa Y; Uesugi S; Mori K; Horiuchi T; Obuchi W; Minami M; Shimada T; Wada C; Yoshida T; Higuchi S
Eur J Pharmacol; 2023 Dec; 961():176184. PubMed ID: 37944847
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr virus-associated extranodal non-Hodgkin's lymphoma of the sinonasal tract and nasopharynx in Thailand.
Mitarnun W; Suwiwat S; Pradutkanchana J
Asian Pac J Cancer Prev; 2006; 7(1):91-4. PubMed ID: 16629523
[TBL] [Abstract][Full Text] [Related]
15. Live Attenuated
Mateos-Chávez AA; Muñoz-López P; Becerra-Báez EI; Flores-Martínez LF; Prada-Gracia D; Moreno-Vargas LM; Baay-Guzmán GJ; Juárez-Hernández U; Chávez-Munguía B; Cabrera-Muñóz L; Luria-Pérez R
Front Immunol; 2019; 10():2562. PubMed ID: 31798573
[TBL] [Abstract][Full Text] [Related]
16. I-kappa-kinase-2 (IKK-2) inhibition potentiates vincristine cytotoxicity in non-Hodgkin's lymphoma.
Al-Katib A; Arnold AA; Aboukameel A; Sosin A; Smith P; Mohamed AN; Beck FW; Mohammad RM
Mol Cancer; 2010 Sep; 9():228. PubMed ID: 20809973
[TBL] [Abstract][Full Text] [Related]
17. Checkpoint Inhibitors Hodgkin Lymphoma and Non-Hodgkin Lymphoma.
Hu B; Jacobs R; Ghosh N
Curr Hematol Malig Rep; 2018 Dec; 13(6):543-554. PubMed ID: 30338457
[TBL] [Abstract][Full Text] [Related]
18. Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma.
Mihara K; Yanagihara K; Takigahira M; Imai C; Kitanaka A; Takihara Y; Kimura A
J Immunother; 2009 Sep; 32(7):737-43. PubMed ID: 19561535
[TBL] [Abstract][Full Text] [Related]
19. ZCL-082, a boron-containing compound, induces apoptosis of non-Hodgkin's lymphoma via targeting p90 ribosomal S6 kinase 1/NF-κB signaling pathway.
Ma C; Liu M; Zhang J; Cai H; Wu Y; Zhang Y; Ji Y; Shan H; Zou Z; Yang L; Liu L; Xu H; Lei H; Liu C; Zhou L; Cao Y; Zhou H; Wu Y
Chem Biol Interact; 2022 Jan; 351():109770. PubMed ID: 34861246
[TBL] [Abstract][Full Text] [Related]
20. Discovery of 5-aminopyrido[2,3-d]pyrimidin-7(8H)-one derivatives as new hematopoietic progenitor kinase 1 (HPK1) inhibitors.
Qiu X; Liu R; Ling H; Zhou Y; Ren X; Zhou F; Zhang J; Huang W; Wang Z; Ding K
Eur J Med Chem; 2024 Apr; 269():116310. PubMed ID: 38479166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]